^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Beta radiation emitter

    Related drugs:
    13h
    Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    temozolomide • AAA603
    14h
    NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SSTR2 (Somatostatin Receptor 2) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate) • AAA603
    18h
    Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients (clinicaltrials.gov)
    P1, N=132, Recruiting, Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    2d
    INDIGO: TheraSphere Japan Pre-Market Study (clinicaltrials.gov)
    P=N/A, N=51, Recruiting, Boston Scientific Corporation
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    2d
    [177Lu]Lu-AKIR001 First-in-human Study (clinicaltrials.gov)
    P1, N=15, Recruiting, Karolinska University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF wild-type
    3d
    A real-world study of 177Lu-PSMA-617 in the treatment of mCRPC (ChiCTR2500114390)
    P=N/A, N=20, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    An Exploratory Study of 177Lu-PSMA-617 in Combination with 177Lu-TBM-001 for the Treatment (Cocktail Therapy) of Metastatic Chemoresistant Prostate Cancer (mCRPC) (ChiCTR2500113787)
    P=N/A, N=30, Recruiting, West Southwest Medical University Affiliated Hospital; West Southwest Medical University Affiliated Hospital
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Radiation Dosimetry, Pharmacokinetics, and Preliminary Efficacy of ¹⁷⁷Lu-HX02 Injection in Patients with Advanced Malignant Solid Tumors (ChiCTR2600116425)
    P1, N=24, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
    New P1 trial
    3d
    Phase I clinical trial to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics and preliminary efficacy of 177Lu-HX02 injection in patients with advanced malignant solid tumors (ChiCTR2600116545)
    P1, N=24, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
    New P1 trial
    4d
    Atypical presentation and association of medullary thyroid carcinoma: reports from a tertiary care center in Northwest India. (PubMed, Endocrinol Diabetes Metab Case Rep)
    The standard management remains surgical resection, with tyrosine kinase inhibitors (TKIs) in RET mutation-positive or RET mutation-negative metastatic cases and/or Lutathera peptide receptor radionuclide therapy (PRRT) used in disseminated disease, and external beam radiotherapy for locally aggressive or infiltrative retaining a limited role...Of the 80 MTC patients reviewed, this case series highlights 10 atypical presentations in nine cases : 3 unusual tumors along with MTC, namely chondrosarcoma, carcinoma prostrate, and ectopic Cushing's syndrome; 4 unusual associations or presenting manifestations: pneumoconiosis masquerading as lung metastasis, Marfanoid habitus in MEN-2A and VHL spectrum disease, 1 with skull metastasis, and 2 cases with TKI-related complications in the form of glomerulonephritis and one patient displayed Marfanoid habitus with a RET mutation but without MEN2B or fibrillin gene mutation, while another developed bowel perforation secondary to lenvatinib therapy emphasizing diagnostic and therapeutic challenges and rare tumor associations...Management of MTC remains complex due to therapy-related complications and resistance. Molecular diagnostics enable better risk stratification and personalized care.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation
    |
    Lenvima (lenvatinib) • Lutathera (lutetium Lu 177 dotatate)
    5d
    Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan (clinicaltrials.gov)
    P4, N=30, Recruiting, Brigham and Women's Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    5d
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
    P1, N=36, Recruiting, Boston Scientific Corporation | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Mar 2026 --> Jul 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    TheraSphere (yttrium 90 microspheres)